Japan Biologics Contract Manufacturing Market Size & Outlook
Japan biologics contract manufacturing market, 2018-2030 (US$M)
Related Markets
Japan biologics contract manufacturing market highlights
- The Japan biologics contract manufacturing market generated a revenue of USD 459.2 million in 2020 and is expected to reach USD 1,316.0 million by 2030.
- The Japan market is expected to grow at a CAGR of 11.1% from 2021 to 2030.
- In terms of segment, mabs was the largest revenue generating product in 2020.
- MABs is the most lucrative product segment registering the fastest growth during the forecast period.
Biologics contract manufacturing market data book summary
| Market revenue in 2020 | USD 459.2 million |
| Market revenue in 2030 | USD 1,316.0 million |
| Growth rate | 11.1% (CAGR from 2020 to 2030) |
| Largest segment | Mabs |
| Fastest growing segment | MABs |
| Historical data | 2018 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | MABs, Recombinant Protein |
| Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, Boehringer Ingelheim, Lonza Group Ltd, AbbVie Inc, Catalent Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Abzena, Samsung BioLogics |
Other key industry trends
- In terms of revenue, Japan accounted for 3.6% of the global biologics contract manufacturing market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China biologics contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,225.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Contract Manufacturing Market Scope
Biologics Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan biologics contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract manufacturing market will help companies and investors design strategic landscapes.
Mabs was the largest segment with a revenue share of 57.91% in 2020. Horizon Databook has segmented the Japan biologics contract manufacturing market based on mabs, recombinant protein covering the revenue growth of each sub-segment from 2018 to 2030.
- Japan Biologics Contract Manufacturing Product Outlook (Revenue, USD Million, 2018-2030)
- MABs
- Recombinant Protein
- Others
- Japan Biologics Contract Manufacturing Indication Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Immunological Disorders
- Cardiovascular Disorders (CVDs)
- Hematological Disorders
- Others
Reasons to subscribe to Japan biologics contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan biologics contract manufacturing market databook
-
Our clientele includes a mix of biologics contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan biologics contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Japan biologics contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan biologics contract manufacturing market size, by product, 2018-2030 (US$M)
Japan Biologics Contract Manufacturing Market Outlook Share, 2020 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
